Mattia Cocco
Research Subjects
Mattia Cocco has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Alasdair Smith
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences
2 shared publications- Alice Dawson
Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
2 shared publications - Beatriz Baragaña
University of Dundee
2 shared publications Chimed Jansen
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences
2 shared publicationsCurtis A. Engelhart
Dept. of Microbiology and Immunology
2 shared publications- Dirk Schnappinger
Department of Microbiology and Immunology, Weill Cornell Medicine, New York, USA
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16459-16482
Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis
There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49, a preclinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimized lead. The work was guided by the first crystal structures of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimized to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.
- 1 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16459-16482
Open AccessDesign and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis
There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49, a preclinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimized lead. The work was guided by the first crystal structures of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimized to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.
- Open Access
Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis
There is currently a public health crisis due to the rise of multi-drug-resistant tuberculosis cases, as well as the rise in number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49 , a pre-clinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl-tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimised lead. The work was guided by the first crystal structure of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimised to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.
Open AccessDesign and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis
There is currently a public health crisis due to the rise of multi-drug-resistant tuberculosis cases, as well as the rise in number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of 49 , a pre-clinical candidate that acted through inhibition of the Mycobacterium tuberculosis lysyl-tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimised lead. The work was guided by the first crystal structure of M. tuberculosis LysRS. The physicochemical and pharmacokinetic properties were optimised to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.
- 17 March 2016
- Published by Wiley in ChemMedChem
- Vol. 11 (16) , 1790-1803
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors
NLRP3 inflammasome plays a key role in the intracellular activation of caspase‐1, processing of pro‐inflammatory interleukin‐1β (IL‐1β), and pyroptotic cell death cascade. The overactivation of NLRP3 is implicated in the pathogenesis of autoinflammatory diseases, known as cryopyrin‐associated periodic syndromes (CAPS), and in the progression of several diseases, such as atherosclerosis, type‐2 diabetes, gout, and Alzheimer's disease. In this study, the synthesis of acrylamide derivatives and their pharmaco‐toxicological evaluation as potential inhibitors of NLRP3‐dependent events was undertaken. Five hits were identified and evaluated for their efficiency in inhibiting IL‐1β release from different macrophage subtypes, including CAPS mutant macrophages. The most attractive hits were tested for their ability to inhibit NLRP3 ATPase activity on human recombinant NLRP3. This screening allowed the identification of 14, 2‐(2‐chlorobenzyl)‐N‐(4‐sulfamoylphenethyl)acrylamide, which was able to concentration‐dependently inhibit NLRP3 ATPase with an IC50 value of 74 μm. The putative binding pose of 14 in the ATPase domain of NLRP3 was also proposed.
- 17 March 2016
- Published by Wiley in ChemMedChem
- Vol. 11 (16) , 1790-1803
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors
NLRP3 inflammasome plays a key role in the intracellular activation of caspase‐1, processing of pro‐inflammatory interleukin‐1β (IL‐1β), and pyroptotic cell death cascade. The overactivation of NLRP3 is implicated in the pathogenesis of autoinflammatory diseases, known as cryopyrin‐associated periodic syndromes (CAPS), and in the progression of several diseases, such as atherosclerosis, type‐2 diabetes, gout, and Alzheimer's disease. In this study, the synthesis of acrylamide derivatives and their pharmaco‐toxicological evaluation as potential inhibitors of NLRP3‐dependent events was undertaken. Five hits were identified and evaluated for their efficiency in inhibiting IL‐1β release from different macrophage subtypes, including CAPS mutant macrophages. The most attractive hits were tested for their ability to inhibit NLRP3 ATPase activity on human recombinant NLRP3. This screening allowed the identification of 14, 2‐(2‐chlorobenzyl)‐N‐(4‐sulfamoylphenethyl)acrylamide, which was able to concentration‐dependently inhibit NLRP3 ATPase with an IC50 value of 74 μm. The putative binding pose of 14 in the ATPase domain of NLRP3 was also proposed.